Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies

Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)

31-Oct-2024 - Merck announced a € 70 million expansion of its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri, USA. This investment will triple existing capacity and enhance the company’s contract development and manufacturing organization ...

Merck Reiterates Confidence in Returning to Sustainable Growth

Tailwind thanks to robust global growth trends in all three business sectors

18-Oct-2024 - Merck is looking confidently toward the future. At the Capital Markets Day, the company shared its expectation of profitable and financially strong growth in the coming years. After the transitional year of 2023, Merck considers the medium-term growth opportunities in its markets to be intact. ...

Merck and Siemens enter Strategic Partnership on Digital Transformation Technology

Merck's cutting-edge production, enabled by Siemens, sets new standards in modular manufacturing

18-Sep-2024 - Merck and Siemens deepened their mutual cooperation aimed at taking smart manufacturing to the next level today. Cedrik Neike, CEO Digital Industries and Member of the Managing Board of Siemens AG, and Kai Beckmann, CEO Electronics business and Member of the Executive Board of Merck, signed a ...

Merck Closes Mirus Bio Acquisition, Bolstering Viral Vector Bioprocessing Offering

Advances Merck’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing

06-Aug-2024 - Merck announced the closing of the transaction to acquire Mirus Bio for approximately US$600million (around €550million), following regulatory clearances and the fulfillment of other customary closing conditions. The acquisition is a strategic step towards Merck's ambition to offer solutions ...

Merck returns to organic sales growth

Merck raises guidance for 2024

02-Aug-2024 - Merck returned to organic sales growth in the second quarter of 2024. EBITDApre remained around stable organically compared with the year-earlier figure, which had been increased by one-time effects. Excluding these one-time effects in the year-earlier quarter, EBITDApre would also have grown ...

Future Insight Prize 2024 Awarded to Johns Hopkins University’s Lauren Gardner

Award is a research grant of € 500,000 for AI-based solutions to prevent future pandemics

12-Jul-2024 - Merck KGaA, Darmstadt, Germany, awarded Professor Lauren Gardner, representing Johns Hopkins University, Baltimore, USA, with the Future Insight Prize 2024 worth € 500,000 for her contributions to develop advanced Artificial Intelligence (AI) systems to help quickly discover and control future ...

Merck Invests € 62 Million in New Quality Control Facility in Darmstadt, Germany

13-Jun-2024 - Merck announces an investment of € 62 million at its Darmstadt headquarters in a new quality control building for its Life Science business. The facility will bring together approximately 135 employees across several departments into one collaborative state-of-the-art space. The nearly 10,000 ...

Merck Completes € 180 Million Investment to Expand Schnelldorf Distribution Center

07-Jun-2024 - Merck, a leading science and technology company, has opened its newly expanded Life Science distribution center in Schnelldorf, Germany. The investment of €180million added 25,000 square meters to the site, almost doubling its size. It now includes a new manual down filling operation and ...

Merck Signs MoU with KAIST to Advance Scientific Collaboration

Multi-dimensional program to build local research capability and startup ecosystem as well as joint R&D projects

31-May-2024 - Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST). The academia-industry cooperation aims at advancing the research and development ecosystem in South Korea for industrial ...

Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million

"This strategic acquisition is a further building block for accelerating growth in the break-through technologies of the future"

24-May-2024 - Merck has signed a definitive agreement to acquire life science company Mirus Bio for US$600million (around €550million). Based in Madison, Wisconsin, USA, Mirus Bio is a specialist in the development and commercialization of transfection reagents. Transfection reagents, such as Mirus Bio's ...